Skip to content

Treatment Of Squamous blepharitis(eyelid disease) With Manjishthadi Ghanavati And Pilla Shukra Nashaka Anjana Varti.

A Clinical Study On Praklinnavartma And Aklinnavartma (Squamous Blepharitis) And Their Management With Manjishthadi Ghanavati And Pilla Shukra Nashaka Anjana Varti

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015200
Enrollment
30
Registered
2018-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H028- Other specified disorders of eyelid Health Condition 2: null- Praklinna vartma and Aklinna vartma (squamous blepharitis)

Interventions

Intervention1: Group A: in this group Pilla Shukra Nashak Anjana Varti Anjana will be given 60 mg per day for one month. Control Intervention1: Group B: in this group Pilla Shukra Nashak Anjana Varti

Sponsors

Institute of Post Graduate Teaching and Research in AyurvedaGujarat Ayurved University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patients presenting with signs and symptoms of Praklinnavartma and Aklinnavartma (Squamous Blepharitis) will be included in the study irrespective of religion, caste and occupation. Symptoms: Whitish material at the lid margin with mild discomfort, irritation,falling of eyelashes, itching, madarosis, foreign body sensation, and burning sensation. Signs: White dandruff like scales on the lid margin and among the lashes. In long standing cases lid margin became thicken.

Exclusion criteria

Exclusion criteria: i.Patients aged below 18 years and above 60 years. ii.Patients having diseases like Corneal Ulcer, Ectropion, Entropion, Trichiasis, Dacryocystitis, Dry Eye, Lagophthalmous, Acute & chronic infective conjunctivitis will be excluded from the study. Patients suffering from specific eyelid disorders like Tumor, Carcinoma or systemic diseases like Diabetes and Bleeding disorders will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
efficacyTimepoint: 2 months

Secondary

MeasureTime frame
safetyTimepoint: 2 months

Countries

India

Contacts

Public ContactLakshmipriya Dei

Institute for Post Graduate Training and Research in Ayurveda,

deilaxmipriya@yahoo.com9228198366

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026